In a move that advocates are saying is a "momentous" win for public health, an Indian court on Friday rejected a bid from multinational pharmaceutical giant Bayer to block a local generic drug company from mimicking their costly cancer drug.
Bayer had attempted to appeal a 2012 decision by India's patent controller, who had argued the monthly $5,500-per-person cost charged by Bayer for the liver and kidney drug Nexevar was too costly for most Indians. The Hyderabad-based Natco Pharma's version of the drug costs roughly 97% less.
Friday's court's decision highlights India's "critical role" in "balancing intellectual property and public health," Leena Menghaney, South Asia regional head of Medicins San Frontieres (MSF)/ Doctor's Without Borders' regional access campaign, told AFP.
Observers are saying that the decision may have far-reaching impact on the drug market because of India's dominance in the pharmaceutical industry. AFPreports:
India'a Lawyers' Collective, another rights group, said the "momentous" judgement held wide-ranging implications for access to other medicines.
India's vast generics industry is a major supplier of cheap copycat, life-saving drugs to treat diabetes, cancer and other diseases afflicting people locally and globally who cannot afford expensive branded versions.
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.